uniQure (NASDAQ:QURE) Shares Gap Up – Should You Buy?

Posted by Brenda Bartman on Nov 4th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report)’s stock price gapped up before the market opened on Monday. The stock had previously closed at $24.83, but opened at $26.22. uniQure shares last traded at $23.3850, with a volume of 1,996,815 shares.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

Positive Sentiment: The FDA accepted uniQure’s biologics license application and granted it Priority Review. The agency set a May 1, 2027 target decision date. If approved, the therapy could become the first disease-modifying treatment for Huntington’s disease. uniQure FDA announcement
Neutral Sentiment: uniQure plans to start screening about 200 patients for a confirmatory trial by year-end. This could support the program, but adds an important execution and evidence milestone for investors to watch. Blockonomi report on QURE and its confirmatory trial
Negative Sentiment: Despite the FDA news, some coverage reported QURE shares falling. Priority Review is not an approval, and the decision is still months away, leaving uncertainty around the FDA’s ultimate assessment of the therapy. MSN report on QURE’s market reaction

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Royal Bank Of Canada dropped their price objective on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a research note on Friday, October 2nd. Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a report on Wednesday, July 29th. William Blair raised uniQure to a “strong-buy” rating in a research report on Wednesday, September 23rd. The Goldman Sachs Group lowered their target price on uniQure from $46.00 to $31.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 30th. Finally, UBS Group began coverage on shares of uniQure in a research report on Thursday, October 15th. They set a “buy” rating and a $48.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.25.

Check Out Our Latest Report on QURE

uniQure Price Performance

The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. The company has a 50 day moving average price of $33.57 and a 200 day moving average price of $29.69.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Seven Fleet Capital Management LP purchased a new stake in shares of uniQure in the 2nd quarter valued at approximately $15,254. IFP Advisors Inc boosted its holdings in shares of uniQure by 39.8% during the second quarter. IFP Advisors Inc now owns 2,780 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 791 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in uniQure in the 3rd quarter valued at approximately $86,000. Fulton Bank N.A. purchased a new stake in shares of uniQure during the second quarter worth $220,000. Finally, Activest Wealth Management bought a new position in uniQure during the third quarter valued at approximately $121,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.